Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
+0.40 (1.65%)
Real-time:   11:40AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.21 - 24.86
52 week 23.59 - 43.63
Open 24.21
Vol / Avg. 97,430.00/507,994.00
Mkt cap 1.08B
P/E     -
Div/yield     -
EPS -0.12
Shares 46.14M
Beta 1.45
Inst. own 104%
Oct 20, 2016
Q3 2016 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Acorda Therapeutics Inc Earnings Release
Jul 28, 2016
Q2 2016 Acorda Therapeutics Inc Earnings Call - Webcast
Jun 8, 2016
Acorda Therapeutics Inc Annual Shareholders Meeting (Estimated)
Jun 8, 2016
Acorda Therapeutics Inc Annual Shareholders Meeting
Jun 7, 2016
Acorda Therapeutics Inc at Goldman Sachs Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -14.87% 2.24%
Operating margin -11.01% 6.90%
EBITD margin - 9.95%
Return on average assets -5.94% 1.02%
Return on average equity -10.82% 1.93%
Employees 535 -
CDP Score - -


420 Saw Mill River Rd
ARDSLEY, NY 10502-2605
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Michael W. Rogers Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Burkhard Blank M.D. Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Andrew Asa Hindman Chief Business Development Officer
Age: 42
Bio & Compensation  - Reuters
David W Lawrence Chief - Business Operations
Age: 57
Bio & Compensation  - Reuters
Lauren M. Sabella Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 52
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters